Physician profile
James Esther
NPI 1609838309
$9,831.08
in general payments reported to CMS, 2019-2025
42 companies · $1,587 in 2025
The $1,587 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,541 · 2020: $525 · 2021: $207 · 2022: $1,640 · 2023: $1,681 · 2024: $1,650 · 2025: $1,587.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,735 · Education: $183.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,734.87 |
| Education | $183.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $1,617.56 | 2019-2025 | |
| Abbvie INC. | $1,118.40 | 2019-2025 | |
| Amgen INC. | $1,098.55 | 2019-2025 | Enbrel, Otezla, Krystexxa |
| Novartis Pharmaceuticals Corporation | $904.34 | 2019-2025 | |
| Janssen Biotech, INC. | $711.23 | 2019-2025 | Tremfya |
| Ucb, INC. | $584.96 | 2019-2025 | Bimzelx, Cimzia |
| Glaxosmithkline, LLC. | $509.22 | 2019-2025 | Shingrix, Arexvy, Benlysta |
| Astrazeneca Pharmaceuticals LP | $497.79 | 2019-2025 | Saphnelo, Farxiga, Airsupra |
| Novo Nordisk INC | $302.41 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Janssen Pharmaceuticals, INC | $290.18 | 2019-2022 | |
| Lilly USA, LLC | $275.43 | 2019-2024 | Mounjaro, Taltz, Trulicity |
| Amarin Pharma, INC. | $205.57 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $149.59 | 2019-2024 | Ofev, Jardiance, Tradjenta |
| Abbott Laboratories | $143.52 | 2022-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Celgene Corporation | $132.87 | 2019 |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Esther listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.